Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F Heigener

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Lung Cancer (Amsterdam, Netherlands)|August 24, 2010
Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC)Sanja Stanisic, Helge G Bischoff, David F Heigener, et al.
Lung Cancer (Amsterdam, Netherlands)|August 24, 2010
Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancerMark Nuijten, David F Heigener, Helge G Bischoff, et al.
Targeted Oncology|September 9, 2014
Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trialDavid F Heigener, José Rodrigues Pereira, Enriqueta Felip, et al.
Targeted Oncology|July 14, 2017
Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 StudyMaya Gottfried, Jaafar Bennouna, Igor Bondarenko, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 17, 2012
Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trialThomas H Fink, Rudolf M Huber, David F Heigener, et al.
Lung Cancer (Amsterdam, Netherlands)|April 10, 2012
The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)Sandra Gottschling, Esther Herpel, Wilfried E E Eberhardt, et al.
Oncology Research and Treatment|May 24, 2014
Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, GermanyDieter Hörsch, Kurt W Schmid, Martin Anlauf, et al.
ERJ Open Research|May 7, 2026
Serotype distribution and coverage by pneumococcal vaccines in hospitalised adults with pneumococcal pneumonia in GermanyDian Karssen, Lisa M Hessels, Grit Barten-Neiner, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Lung Cancer (Amsterdam, Netherlands)|August 24, 2010
Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC)Sanja Stanisic, Helge G Bischoff, David F Heigener, et al.
Lung Cancer (Amsterdam, Netherlands)|August 24, 2010
Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancerMark Nuijten, David F Heigener, Helge G Bischoff, et al.
Targeted Oncology|September 9, 2014
Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trialDavid F Heigener, José Rodrigues Pereira, Enriqueta Felip, et al.
Targeted Oncology|July 14, 2017
Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 StudyMaya Gottfried, Jaafar Bennouna, Igor Bondarenko, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 17, 2012
Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trialThomas H Fink, Rudolf M Huber, David F Heigener, et al.
Lung Cancer (Amsterdam, Netherlands)|April 10, 2012
The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)Sandra Gottschling, Esther Herpel, Wilfried E E Eberhardt, et al.
Oncology Research and Treatment|May 24, 2014
Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, GermanyDieter Hörsch, Kurt W Schmid, Martin Anlauf, et al.
ERJ Open Research|May 7, 2026
Serotype distribution and coverage by pneumococcal vaccines in hospitalised adults with pneumococcal pneumonia in GermanyDian Karssen, Lisa M Hessels, Grit Barten-Neiner, et al.
Pageof 3